for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AstraZeneca plc

AZN.L

現在値

7,479.00GBp

変化

61.00(+0.82%)

出来高

1,210,411

本日のレンジ

7,422.00

 - 

7,507.00

52週レンジ

6,736.00

 - 

10,120.00

∙ 約20分前の相場を表示しています。

適時開示

Astrazeneca Announces U.S. Clearance Of Proposed Acquisition Of Alexion

April 16 (Reuters) - AstraZeneca PLC <AZN.L>::ASTRAZENECA PLC - US CLEARANCE OF PROPOSED ACQUISITION OF ALEXION.ASTRAZENECA - ACQUISITION REMAINS EXPECTED TO CLOSE IN Q3 2021.ASTRAZENECA - SHAREHOLDER VOTING OB DEAL ANTICIPATED ON 11 MAY 2021.

Oxford Says Risk Of Rare Blood Clotting Higher For COVID-19 Than For Vaccines

April 15 (Reuters) - University of Oxford: :OXFORD - REPORTED RISK OF RARE BLOOD CLOTTING KNOWN AS CEREBRAL VENOUS THROMBOSIS FOLLOWING COVID-19 INFECTION IS AROUND 100 TIMES GREATER THAN NORMAL.OXFORD - REPORTED RISK OF RARE BLOOD CLOTTING FOLLOWING COVID-19 INFECTION IS SEVERAL TIMES HIGHER THAN IT IS POST-VACCINATION OR FOLLOWING INFLUENZA.OXFORD UNIVERSITY- REPORT SAYS CVT IS MORE COMMON AFTER COVID-19 THAN IN ANY OF COMPARISON GROUPS, WITH 30% OF THESE CASES OCCURRING IN UNDER 30S.OXFORD - REPORT SAYS COMPARED TO AZ-OXFORD VACCINE, RISK OF A CVT FROM COVID-19 IS ABOUT 8 TIMES GREATER.Further company coverage: AZN.L. ((Reuters.Briefs@thomsonreuters.com;)).

EMA To Provide Further Context On AstraZeneca Vaccine Risk Of Very Rare Blood Clots

April 14 (Reuters) - European Medicines Agency::EMA SAYS ASTRAZENECA'S COVID-19 VACCINE: EMA TO PROVIDE FURTHER CONTEXT ON RISK OF VERY RARE BLOOD CLOTS WITH LOW BLOOD PLATELETS.EMA SAYS EMA IS UNDERTAKING A REVIEW OF VACCINATION DATA AND DATA ON DISEASE EPIDEMIOLOGY.EMA SAYS REVIEW BY CHMP WILL ENABLE AUTHORITIES TO PUT RISKS OF VAXZEVRIA INTO CONTEXT OF BENEFITS OF ONGOING VACCINATION CAMPAIGNS.EMA SAYS CHMP WILL ALSO CONSIDER WHETHER TO UPDATE RECOMMENDATIONS FOR A SECOND DOSE OF VAXZEVRIA IN THOSE WHO HAVE ALREADY RECEIVED THE FIRST DOSE.

AstraZeneca Says Tagrisso Approved In China In Early Lung Cancer

April 14 (Reuters) - AstraZeneca PLC <AZN.L>::ASTRAZENECA PLC - TAGRISSO APPROVED IN CHINA IN EARLY LUNG CANCER.ASTRAZENECA - APPROVAL BASED ON UNPRECEDENTED RESULTS FROM ADAURA PHASE III TRIAL.ASTRAZENECA - APPROVAL BASED ON UNPRECEDENTED RESULTS FROM ADAURA PHASE III TRIAL WHERE TAGRISSO REDUCED RISK OF DISEASE RECURRENCE OR DEATH BY 80%.ASTRAZENECA- APPROVAL FOR ADJUVANT TREATMENT OF PATIENTS WITH EARLY-STAGE EPIDERMAL GROWTH FACTOR RECEPTOR-MUTATED NON-SMALL CELL LUNG CANCER.

U.S. FDA Official Says One Death Reported Due To Blood Clot Event After J&J Vaccine

April 13 (Reuters) - :U.S. FDA OFFICIAL SAYS ONE DEATH REPORTED DUE TO RARE BLOOD CLOT AFTER J&J VACCINE, ONE PATIENT IS IN CRITICAL CONDITION.U.S. FDA OFFICIAL SAYS HEALTH CARE PROVIDERS WHO SEE WITH EITHER A LOW BLOOD PLATELET COUNT OR BLOOD CLOTS SHOULD ESTABLISH WHETHER INDIVIDUAL HAS RECENTLY BEEN VACCINATED.FOR PEOPLE WHO GOT J&J COVID-19 VACCINE MORE THAN A MONTH AGO, RISK OF BLOOD CLOT EVENTS IS VERY LOW AT THIS TIME- FDA OFFICIAL.WE ARE NOT SEEING CLOTTING EVENTS WITH LOW PLATELET COUNT WITH COVID-19 VACCINES FROM PFIZER/BIONTECH AND MODERNA - CDC OFFICIAL.U.S. FDA OFFICIAL EXPECTS PAUSE IN USE OF J&J VACCINE TO BE A "MATTER OF DAYS".U.S. HEALTH OFFICIAL SAYS LEADING HYPOTHESIS IS THE J&J COVID-19 VACCINE IN VERY RARE CASES IS CAUSING AN IMMUNE RESPONSE THAT LEADS TO THESE "EXTREMELY RARE" BLOOD CLOTS.U.S. FDA OFFICIAL SAYS RECOMMENDATION TO PAUSE J&J COVID-19 VACCINE IS NOT A MANDATE.U.S. FDA OFFICIAL SAYS UNCLEAR AT THIS TIME IF THERE IS ANY ASSOCIATION WITH ORAL CONTRACEPTIVE PILL IN INDIVIDUALS WHO HAD BLOOD CLOTS AFTER J&J VACCINE.U.S. FDA OFFICIAL PETER MARKS DESCRIBES J&J VACCINE PAUSE AS "TEMPORARY" AND SAYS IT SHOULD NOT IMPACT OVERALL U.S. VACCINATION EFFORTS.FDA OFFICIAL SAYS "IT'S PLAINLY OBVIOUS" THAT THE EVENTS WITH J&J COVID-19 VACCINE LOOK "VERY SIMILAR" TO CASES REPORTED IN RELATION TO ASTRAZENECA VACCINE.Further company coverage: JNJ.N. ((Reuters.Briefs@thomsonreuters.com;)).

EMA Starts Safety Signal Review To Assess Reports Of Capillary Leak Syndrome In People Who Got AstraZeneca Shot

April 9 (Reuters) - European Medicines Agency::PRAC CONCLUSION ON VERY RARE CASES OF UNUSUAL BLOOD CLOTS WITH LOW BLOOD PLATELETS WITH VAXZEVRIA (ASTRAZENECA’S COVID-19 VACCINE).EMA SAYS PRAC HAS STARTED A REVIEW OF A SAFETY SIGNAL TO ASSESS REPORTS OF CAPILLARY LEAK SYNDROME IN PEOPLE WHO WERE VACCINATED WITH VAXZEVRIA.EMA - PRAC CONCLUDED UNUSUAL BLOOD CLOTS WITH LOW BLOOD PLATELETS SHOULD BE LISTED AS VERY RARE SIDE EFFECTS OF VAXZEVRIA (PREVIOUSLY COVID-19 VACCINE ASTRAZENECA).EMA SAYS AT THIS STAGE, NOT YET CLEAR WHETHER THERE IS A CAUSAL ASSOCIATION BETWEEN ASTRAZENECA VACCINATION AND REPORTS OF CAPILLARY LEAK SYNDROME.EMA, ON ASTRAZENECA VACCINE, SAYS IN CASES CAUSAL RELATIONSHIP IS CONFIRMED/CONSIDERED LIKELY, REGULATORY ACTION NECESSARY IN ORDER TO MINIMISE RISK.EMA - PRAC STARTED REVIEW OF A SAFETY SIGNAL TO ASSESS REPORTS OF THROMBOEMBOLIC EVENTS IN PEOPLE WHO RECEIVED COVID-19 VACCINE JANSSEN.EMA SAYS FOUR SERIOUS CASES OF UNUSUAL BLOOD CLOTS WITH LOW BLOOD PLATELETS HAVE BEEN REPORTED POST-VACCINATION WITH COVID-19 VACCINE JANSSEN.

AstraZeneca Says Updates To UK And EU Labels For COVID-19 Vaccine Requested

April 7 (Reuters) - AstraZeneca PLC <AZN.L>::ASTRAZENECA - UPDATE FOLLOWING MHRA AND EMA DECISIONS ON ASTRAZENECA'S COVID-19 VACCINE.ASTRAZENECA - UPDATES TO THE UK AND EU LABELS FOR THE VACCINE HAVE BEEN REQUESTED BY THE REGULATORS..ASTRAZENECA - HAS BEEN ACTIVELY COLLABORATING WITH THE REGULATORS TO IMPLEMENT THESE CHANGES TO THE PRODUCT INFORMATION.ASTRAZENECA - ALREADY WORKING TO UNDERSTAND THE INDIVIDUAL CASES, EPIDEMIOLOGY AND POSSIBLE MECHANISMS THAT COULD EXPLAIN THESE EXTREMELY RARE EVENTS..ASTRAZENECA - ALMOST 200 MILLION INDIVIDUALS HAVE RECEIVED THE ASTRAZENECA COVID-19 VACCINE AROUND THE WORLD.

EMA Finds Possible Link Between Astrazeneca's Vaccine To Very Rare Cases Of Blood Clots

April 7 (Reuters) - European Medicines Agency::ASTRAZENECA’S COVID-19 VACCINE: EMA FINDS POSSIBLE LINK TO VERY RARE CASES OF UNUSUAL BLOOD CLOTS WITH LOW BLOOD PLATELETS.EMA SAYS IN REACHING CONCLUSION, COMMITTEE TOOK INTO CONSIDERATION ALL CURRENTLY AVAILABLE EVIDENCE, INCLUDING THE ADVICE FROM AN AD HOC EXPERT GROUP.EMA SAYS CONCLUDED TODAY THAT UNUSUAL BLOOD CLOTS WITH LOW BLOOD PLATELETS SHOULD BE LISTED AS VERY RARE SIDE EFFECTS OF VAXZEVRIA.EMA SAYS PEOPLE WHO RECEIVED VACCINE SHOULD SEEK MEDICAL ASSISTANCE IMMEDIATELY IF DEVELOP SYMPTOMS OF COMBINATION OF BLOOD CLOTS, LOW BLOOD PLATELETS.EMA - PRAC NOTED THAT BLOOD CLOTS OCCURRED IN VEINS IN BRAIN AND THE ABDOMEN (SPLANCHNIC VEIN THROMBOSIS) AND IN ARTERIES.EMA - PRAC HAS REQUESTED NEW STUDIES AND AMENDMENTS TO ONGOING ONES TO PROVIDE MORE INFORMATION AND WILL TAKE ANY FURTHER ACTIONS NECESSARY..EMA-ONE PLAUSIBLE EXPLANATION FOR COMBINATION OF BLOOD CLOT, LOW BLOOD PLATELETS IS IMMUNE RESPONSE, LEADING TO CONDITION SIMILAR TO ONE SEEN SOMETIMES IN PATIENTS TREATED WITH HEPARIN.EMA-USE OF VACCINE DURING VACCINATION CAMPAIGNS AT NATIONAL LEVEL TO TAKE INTO ACCOUNT PANDEMIC SITUATION, VACCINE AVAILABILITY IN INDIVIDUAL MEMBER STATE.

Start-Up Behind Astrazeneca Vaccine Files U.S. IPO - FT

April 7 (Reuters) - :VACCITECH, THE START-UP BEHIND ASTRAZENECA VACCINE, HAS CONFIDENTIALLY FILED FOR IPO IN THE U.S. - FT.

Emergent Biosolutions Says Receives Modified Task Order From U.S. HHS To Support Further Expansion Of Manufacturing Capacity For Johnson & Johnson's COVID-19 Vaccine

April 4 (Reuters) - Emergent BioSolutions Inc <EBS.N>::EMERGENT BIOSOLUTIONS ON TRACK WITH RESPECT TO COVID-19 CONTRACTUAL COMMITMENTS; RECEIVES MODIFIED TASK ORDER FROM THE U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES TO SUPPORT THE OPPORTUNITY FOR FURTHER EXPANSION OF MANUFACTURING CAPACITY FOR JOHNSON & JOHNSON’S COVID-19 VACCINE.HHS HAS INCREASED EMERGENT'S TASK ORDER BY $23 MILLION TO PURCHASE ADDITIONAL BIOLOGICS MANUFACTURING EQUIPMENT.CONTINUES TO BE ON TRACK WITH MANUFACTURING AGREEMENTS RELATED TO COVID-19 VACCINES,CONFIRMED NO CHANGES TO ITS FINANCIAL GUIDANCE FOR 2021.$23 MILLION TO BE USED FOR PURCHASE OF BIOLOGICS MANUFACTURING EQUIPMENT SPECIFIC TO JOHNSON & JOHNSON'S COVID19 VACCINE.EXPECTS TO ALIGN WITH U.S.,ASTRAZENECA ON A MUTUALLY AGREED RAMP DOWN OF MANUFACTURING FOR ASTRAZENECA'S COVID-19 VACCINE BULK DRUG SUBSTANCE.CONTINUES TO OWN&OPERATE FACILITY CONSISTENT WITH OBLIGATIONS TO ALL OF CUSTOMERS AND IN COMPLIANCE WITH REGULATORY STANDARDS."EMERGENT'S TOP PRIORITY CONTINUES TO BE STRENGTHENING OF SUPPLY CHAIN FOR JOHNSON & JOHNSON'S VITALLY NEEDED COVID-19 VACCINE".

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up